Form D · Pharmaceuticals

Dova Pharmaceuticals, Inc.

Charlottesville, VA · CIK 0001685071

Offering snapshot reported Sep 23, 2016 · SEC filing

Reported sold: $10M
Investors reported: 1
Minimum accepted: $2.5M
First sale: Sep 19, 2016

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 23, 2016	Initial	$10,000,000	No comparison	1	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0 (estimated)
Finders' fees: $0 (estimated)
Form D file number: 021-271207

The Issuer's Board may have one or more closings at any time and from time to time after receiving investments totaling $10,000,000. The Issuer's Board may also accept less than the stated minimum investment amount of $2,500,000 in its discretion.

The Issuer may in the future retain a broker in connection with the offering but has not yet done so.

Source: Form D, filed Sep 23, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Damian De Goa	Executive, Promoter
Hossein Ekrami	Director
Bkb Growth Investments, Llc	Promoter
Pbm Capital Investments Llc	Promoter
Paul B. Manning	Director, Executive, Promoter
James C. Reebals	Executive, Promoter
Eugene R. Scavola	Executive, Promoter
Russell T. Schundler	Executive, Promoter
John A. Stalfort	Director, Executive, Promoter

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

200 Garrett Street Suite S
Charlottesville, VA, 22902